Reference Number 423961


Protocol Number: B3166

Protocol Version: Revision 4

Version Date: 06 Sep 2022

Return to Study Synopsis

"Biomérieux" | Yellow-green and blue circle encompassing text

Study Investigators

  • PI: Danielle Davison, MD
  • Sub-I: Katrina Hawkins, MD
  • Sub-I: Lynn Abell, MD
  • Sub-I: Mustafa Al-Mashat, MD
  • Sub-I: Yoosif Abdalla, MD


Study Objectives

The objective of this trial is to identify suitable storage conditions for samples tested using the VIDAS® NCLTM CCL14 test for the full measuring range of the assay (0.2 ng/mL to 30 ng/mL).


Patient Population

See inclusion criteria below.


Inclusion Criteria

This study will utilize samples that have been collected from individuals who have consented to the use of samples in the AST-134 study and related studies such as the VIDAS® NCLTM CCL14 trial.

  • Males and females 21 years of age or older
  • Receiving care in an intensive care unit
  • Expected to remain in the ICU for at least 48 hours after enrollment
  • Use of indwelling urinary catheter as standard care at the time of enrollment
  • Subject must have acute kidney injury (KDIGO Stage 2 or Stage 3) at the time of sample collection
  • Urine sample must be collected within 36 hours of meeting KDIGO Stage 2 criteria
  • Written informed consent provided by patient or legally authorized representative (LAR)


Exclusion Criteria

  • Prior kidney transplantation
  • Comfort-measures-only status
  • Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment
  • Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic); (NOTE: HIV or hepatitis testing need not be performed for enrollment in this study.)
  • Special populations, pregnant women, prisoners or institutionalized individuals



VIDAS patients are automatically co-enrolled in this protocol once enrolled into AST-134 TURQUOISE